ASMB — ASSEMBLY BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1426800 ·
Last close
$22.50
Market Cap
$460.74M
52W High
$39.71
52W Low
$19.20
ADV30
250,083
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,956,000 | — | -23,415,000 | -20,256,000 | 325,286,000 | 29,073,000 | 26,493,000 |
| Jun 2026 | 13,374,000 | — | -6,344,000 | -3,857,000 | 330,832,000 | 32,286,000 | 25,183,000 |
| Mar 2026 | 8,213,000 | — | -11,370,000 | -9,079,000 | 235,508,000 | 31,120,000 | 36,898,000 |
| Dec 2025 | 42,469,000 | — | 19,799,000 | 22,090,000 | 257,590,000 | 58,450,000 | 50,839,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,481,000
Investing CF
$-234,511,000
Financing CF
$281,272,000
CapEx
$-43,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.79
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-844,983,000
Inventory
—
Receivables
$822,000
ST Investments
$288,075,000
EBIT TTM
$-8,798,000
Pretax Income TTM
$-42,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$67,012,000
EBITDA
$-21,228,000
Free Cash Flow
$-36,266,248
Enterprise Value
$120,424,392
Total Cash
$314,262,016
Total Debt
$2,207,000
Shares Out
20,477,244
Trailing EPS
$0.75
Book Value
$14.67
ROE
-4.6%
ROA
-4.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 72,303,000 | -12,118,000 | -6,122,000 | 257,590,000 | 50,839,000 | 206,751,000 | -41,093,000 |
| Dec 2024 | 28,520,000 | -45,420,000 | -40,177,000 | 119,168,000 | 85,809,000 | 33,359,000 | -51,117,000 |
| Dec 2023 | 7,163,000 | -64,646,000 | -61,228,000 | 136,823,000 | 95,726,000 | 41,097,000 | 22,743,000 |
| Dec 2022 | 0 | -94,114,000 | -93,092,000 | 101,794,000 | 19,130,000 | 82,664,000 | -84,463,000 |
TTM Snapshot
Revenues TTM
$74,845,000
NetIncome TTM
$-42,000
OpCashFlow TTM
—
Assets (Latest)
$330,832,000
Forward EPS
$-2.57
Max Pain — expiry 2026-12-18
max pain strike: $15.00 · spot: $22.39 · call oi: 1,084 · put oi: 170
Expected Move to 2026-12-18:
±$4.20
(18.76%) —
implied range
$18.19 –
$26.59
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | $465.04M | $3.70 | — |
| STTK | Shattuck Labs, Inc. | $467.46M | $4.59 | — |
| DMAC | DiaMedica Therapeutics Inc. | $452.16M | $8.38 | — |
| KMDA | KAMADA LTD | $470.92M | $8.16 | — |
| AMRN | AMARIN CORP PLC\UK | $473.82M | $11.27 | — |
News headlines (Yahoo Finance, 1h cache)
Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 21:15 · Yahoo
Assembly Biosciences: Q3 Earnings Snapshot
2026-11-12 21:10 · Yahoo
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
2026-11-12 21:00 · Yahoo
Assembly Biosciences to Participate in Upcoming Investor Conferences
2026-11-02 21:00 · Yahoo
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
2026-10-29 20:00 · Yahoo
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
2026-10-05 14:00 · Yahoo
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
2026-09-10 20:15 · Yahoo
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services
2026-09-08 13:48 · Yahoo
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?
2026-09-07 13:55 · Yahoo
Should You Buy Assembly Biosciences (ASMB) After Golden Cross?
2026-09-04 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.